The ISGIDAR NEWSLETTER

VOL. 25, NO. 1	April, 1999

The 1999 annual ISGIDAR Scientific Meeting will be held Saturday 12 June 1999 at the Acapulco Princess Resort (Princessa 1 meeting room) in Acapulco, Mexico. As usual, the meeting will be held as a satellite session immediately preceding the annual scientific meeting of the College on Problems of Drug Dependence. ISGIDAR registration will begin at 8:30 am. The registration fee is $50; this is a necessary increase from last year to cover the meeting costs (ISGIDAR is not getting rich by charging this registration fee - it hopes to break even). There will be two coffee breaks with the first break at the beginning of the session in which there will be a limited number of pastries. Luncheon will also be held and will cost from $12-$15 (see below). Paper presentations will be scheduled between 9 am and 5 pm, and the business meeting will be held from 5 to 5:30 pm.

A couple of notes about this year's meeting: We are especially pleased to announce that Dr. Joseph Brady, currently Professor of Psychiatry at the Johns Hopkins University School of Medicine, has accepted an invitation to address ISGIDAR. Also on the program there will be a small symposium on the proper control procedures for accessing the specificity of potential drug abuse medications. Many of ISGIDAR members are involved with developing medications to treat drug abuse disorders and this symposium should be particularly timely and interesting. Our business meeting this year is particularly important for we will be electing new officers. Members should make an extra attempt to attend the business meeting for this reason alone. Other topics for discussion during the business meeting will at least include the status of recent applicants as members as well as the membership process in general. If you would like to include other specific business topics please email them to Patrick Beardsley @ pbeardsl@hsc.vcu.edu.

All are highly encouraged to present data at this year's meeting. It is likely that attendance will be down from last year because we are meeting at a foreign site so the atmosphere will be even more intimate and informal than last year. To present a paper at the ISGIDAR meeting, please send an abstract by May 20, 1999 to Patrick Beardsley at the address listed above. Abstracts should conform generally to the format used for presentations at CPDD but need not be on the CPDD abstract form nor is it necessary for them to fit into the "CPDD abstract box". Please note that papers submitted to ISGIDAR should not also be presented at CPDD. The amount of time available for each talk will depend on the number of papers submitted but will not be less than 20 minutes.

1999 TRAVEL AWARD:STUDENT PAPER COMPETITION

ISGIDAR will again sponsor a Student Paper Competition Award for a new investigator to present a paper on drug self-administration research. Up to $500 in reasonable and documented travel costs will be paid to the winner to present a paper at ISGIDAR. Payment will be made upon submission of travel receipts to the ISGIDAR Treasurer. Those who do not receive the award, but who receive good reviews will be encouraged to present their papers at the ISGIDAR meeting. Submission deadline: May 20, 1999.

ELIGIBILITY:

• Applicants must be enrolled in a graduate program and be working toward a doctorate or have received their doctorate within the last five years (after June 1, 1994).
• Applicants who are not ISGIDAR members must be sponsored by an ISGIDAR member.The research to be reported at ISGIDAR must not already be published in its entirety.

MANUSCRIPT REQUIREMENTS:

• Papers should not be more than 10 pages excluding figures and references.
The length and scope of the paper should be consistent with a 20-25 minute slide presentation.
• Please include paper title, name, address, phone number and author's signature on the cover page of the manuscript. The signature and typed name of the author's sponsor should also appear on the cover page after a statement indicating that the applicant made a significant scientific contribution to the research. Submit four copies, double-spaced.

REVIEW:

SUBMIT MANUSCRIPTS TO: Patrick M. Beardsley, Ph.D.,
Medical College of Virginia, Dept. of Pharmacology & Toxicology, P.O. Box 980613, 410 North 12th St., Smith Bldg. #756A, Richmond, VA 23298-0613

ISGIDAR LUNCHEON

We are again arranging to have lunch catered by the hotel, so that we can eat together and continue discussions from the morning session. The luncheon will be held in the Princessa 2 meeting room at the hotel. The lunch will cost about $12-15 per person. Because in past years we have had difficulty estimating the number of people wanting lunch, which has resulted in some cases in large drains in the ISGIDAR treasury and in other cases in pleading and begging with hotel staff, we are asking that those wishing to join us for the ISGIDAR lunch indicate in advance, preferably by email (but you can use snail mail or fax if need be), to Patrick Beardsley at the address below. Please let the various members of your lab who will be attending ISGIDAR, but who might not receive the Newsletter, know about lunch. While there will be a limited number of seats available for those failing to indicate in advance their desire for lunch, these will be strictly limited and will be available on a first come first serve basis. Luncheon requests to:

pbeardsl@hsc.vcu.edu OR via snail mail:

Patrick M. Beardsley, Ph.D., Medical College of Virginia, Dept. of Pharmacology & Toxicology, P.O. Box 980613, 410 North 12th St., Smith Bldg. #756A, Richmond, VA 23298-0613; FAX: (804) 828-2117

ISGIDAR Internet Discussion List
"ISGIDAR-L@lists.vcu.edu"

Our ISGIDAR Discussion/News Group is again active. The President of ISGIDAR had sent out the invitation below, via email, to all members of ISGIDAR given the email addresses available in the ISGIDAR database at the time. Many of these addresses were incorrect because LISTSERVER error messages were returned. If you wish to receive discussions via this discussion group please follow the directions below contained in the copy of Patrick's original emailing. We're sorry if you didn't receive this original invitation.
Copy of the original email invitation:

Through the able assistance of Jonathan Kamien we have reestablished the ISGIDAR Discussion List. You are being contacted because you were either a previous subscriber to this newsgroup, you are an ISGIDAR member, or you have attended a recent ISGIDAR meeting. We apologize if you have received this message more than once. If you are interested in subscribing to the new ISGIDAR Discussion List, please send an email message to the following address: listserv@lists.vcu.edu

with the following one line in the body of the message:

SUBSCRIBE ISGIDAR-L your name

Even if you were a previous subscriber you will have to subscribe now as directed.

We were unable to send this message to several people who should also have received it because we were lacking their email address. Also, there are likely some to whom we sent this message but an out-of-date email address was used. Please pass the word on to interested folks that if they did not receive this email and want to subscribe to the news group they can do so as directed above. We apologize to those whom we failed to contact.

I am looking forward to an active newsgroup. In the past, this news group has provided subscribers helpful suggestions to those in need of assistance as well as having served as a medium for advertising open positions in labs, etc. I look forward to its rebirth.

Patrick M. Beardsley, Ph.D.
President, International Study Group Investigating Drugs as Reinforcers

P.S. Please subscribe soon for I, and some other members of ISGIDAR have pending messages that they wish to circulate. Thanks again.

Recent Publications: ISGIDAR Member Bibliographies

• Nicholson, K.L., Jones, H.E. and Balster, R.L. Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine. Behavioural Pharmacology 9:231-243, 1998.
• Wiley, J.L., Dance, M.E. and Balster, R.L. Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist. Psychopharmacology 140:503-509, 1998.

• Heishman, S. J. (1998). What aspects of human performance are truly enhanced by nicotine? Addiction, 93, 317-320.
• Fant, R. V., Heishman, S. J., Bunker, E. B., & Pickworth, W. B. (1998). Acute and residual effects of marijuana in humans. Pharmacology Biochemistry and Behavior, 60, 777-784.
• Henningfield, J. E., & Heishman, S. J. (1998). Behavioral toxicology of nicotine. In N. L. Benowitz (Ed.), Nicotine safety and toxicity (pp. 133-146). New York: Oxford.
• Heishman, S. J., Singleton, E. G., & Crouch, D. J. (1998). Laboratory validation study of Drug Evlauation and Classification program: Alprazolam, d-amphetamine, codeine, and marijuana. Journal of Analytical Toxicology, 22, 503-514.
• Bell, S. L., Taylor, R. C., Singleton, E. G., Henningfield, J. E., & Heishman, S. J. (1999). Smoking after nicotine deprivation enhances cognitive performance and decreases tobacco craving. Nicotine and Tobacco Research, 1, 45-52.
• Heishman, S. J., & Henningfield, J. E. (in press). Is caffeine a drug of dependence? Criteria and comparisons. In B. S. Gupta & U. Gupta (Eds.), Caffeine and behavior: Current views and research trends (pp. 139-152). Boca Raton, FL: CRC Press.
• Heishman, S. J., Weingartner, H. J., & Henningfield, J. E. (in press). Selective deficits in reflective cognition of polydrug abusers: Preliminary findings. Psychology of Addictive Behaviors.
• Rothman, R. B., Gorelick, D. A., Heishman, S. J., Eichmiller, P. R., Hill, B. H., Norbeck, J., & Liberto, J. G. (in press). An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. Journal of Substance Abuse Treatment.

• Zhang, C., Izenwasser, S. Katz, J.L., Terry, P., and Trudell, M.L. Synthesis and dopamine transporter affinity of the four stereoisomers of (±)-2-methoxycarbonyl-7-methyl-3-phenyl-7-azabicyclo[2.2.1]heptane. Journal of Medicinal Chemistry, 41: 2430-2435, 1998.
• Lomenzo, S.A., Izenwasser, S., Katz, J.L., and Trudell, M.L. The effects of alkyl substituents at the 6-position of cocaine analogues on dopamine transporter binding affinity and dopamine uptake inhibition. In: A.H. Newman (Ed.). The Dopamine Transporter as a Molecular Target for the Development of Cocaine Abuse Therapeutics, Medicinal Chemistry Research, 8: 35-42, 1998.
• Bergman, J. and Katz, J.L. Behavioral Pharmacology of Cocaine. In: S.T. Higgins and J.L. Katz (Eds.). Cocaine Abuse Research: Pharmacology, Behavior, and Clinical Applications. San Diego: Academic Press, 1998, pp. 51-79.
• Katz, J. L., Izenwasser, S., Kline, R.H., Allen, A.C., Newman, A.H. Novel 3 -diphenyl-methoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. Journal of Pharmacology and Experimental Therapeutics, 288: 302-315, 1999.
• Tolliver, B.K., Newman, A.H., Katz, J.L., Ho, L.B., Fox, L.M., Hsu, K., Jr., and Berger, P.S. Behavioral and neurochemical effects of dopamine transporter ligands alone and in combination with cocaine: Characterization of 4-chlorobenztropine in vivo. Journal of Pharmacology and Experimental Therapeutics, 289: 110-122, 1999.

POSITIONS AVAILABLE

MEDICAL COLLEGE OF VIRGINIA, DEPARTMENT OF PHARMACOLOGY & TOXICOLOGY

• pharmacology of dopamine D3 receptor ligands
• pharmacology of excitatory amino acid agents
• development of medications for the treatment of drug-dependency disorders
• harmacology of behaviorally-active inhalation agents
• effects of chemicals on the probability of relapse to cocaine and heroin self-administration

LOUISIANA STATE UNIVERSITY MEDICAL CENTER, DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY

NIDA INTRAMURAL RESEARCH PROGRAM

UNIVERSITY OF FLORIDA, DEPARTMENT OF PSYCHOLOGY

UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, DEPARTMENT OF PHARMACOLOGY & TOXICOLOGY

MCLEAN HOSPITAL / HARVARD MEDICAL SCHOOL

LSU MEDICAL CENTER - NEW ORLEANS, DEPARTMENT OF PHARMACOLOGY